GLP-1 treatments such as Semaglutide (under commercial names Ozmpic and Wegovy) written by Novo Nordisk A/S NYSE: NVO The story of the medical sector is likely to be the hottest in 2024. With its presentation to Tirzepatide (bearing the Mounjaro and Zepbound brand), Eli Lilly and Co. New York: Li Another major Pharma player in this new type of treatment for diabetes and obesity was. The popular revenue gains followed these treatments. ELI Lilly Sales Mounjaro witnessed an annual basis on an annual basis in the third quarter of 2024, overcoming the Novo Nordisk to a large extent thanks to the availability of the offer.
Elie Lily and Partners today
Elie Lily and Partners
- 52 weeks
- $ 637.00
▼
972.53 dollars
- Profit
- 0.64 %
- P/E ratio.
- 87.37
- The target price
- 997.22 dollars
However, Eli Lilly’s shares have been irregular in recent months. Although the stock increased by 25.1 % in the year leading to January 24, 2025, in the back half of that time period – six months from late July 2024 to January – decreased by more than 4 %. This is all despite the high share price of about $ 973, which was achieved in 2024 on Tirzepatide sales momentum.
Investors may wonder naturally what is going on with Eli Lilly and the drug giant they may expect next year. Besides the presentations of the current GLP-1, the ELI Lilly investors may attract their birth control pills version of Tirzepatide-on the horizon in 2026-as well as for oncology products. In fact, the company’s pipeline is generally impressive.
What can be expected from popular GLP-1 treatments
Many Eli Lilly’s momentum was in the last quarters due to Mounjaro and Zepbound. However, in January 2025The company Update 2024 revenue directions I offered instructions for the new year, which Many investors found disappointing. Sales are still prosperous-David A. Ricks, CEO and Executive Director, said that the American Al-Azida Market (which includes GLP-1) grew by 45 % on an annual basis during the last quarter of 2024. However, the company does not expect that Sales of two GLP-1 treatments will grow at the forefront at the beginning.
Investors may be in mind that Eli Lily is still offering significant growth in the upper lines of 2024, especially for 2025. Elie Lily’s concerted effort to support GLP-1 production. The company expects to produce more capable doses of at least 60 % in the first half of 2025 for the same period in 2024.
An additional reason for replacement about the possibility of Zepbound in particular in 2025 and beyond – in 2024, The Food and Drug Administration agreed to this medicine To treat moderate to acute sleeping (OSA) in adults with obesity. Zepbound is the first approved drug from the FDA to treat OSA, and open a new part of the market and gives Zepbound a possible advantage over the other GLP-1 currently available.
New products to see them
OrforiPron is the ELI Lilly version of Tirzepatide, and The company expects data On the mid-year and potential approval of the first few months of 2026, given that the GLP-1 drugs currently require regular injection, it is possible that many patients will choose the option of birth control pills directly if it is given it option. Besides, eli Lilly has another GLP-1 candidate in the works that seem to be the strongest yet. Ritatotide It has been proven to produce the greatest weight loss of any GLP-1.
With the popularity of GLP-1, it is easy to forget that Eli Lilly has a deep list of many other powerful candidates as well. In particular, analysts prefer the list of tumors of the company, including Verzenio, an oral drug used to treat certain types of breast cancer. Sales of this drug alone reached approximately $ 4 billion for the third quarter of 2024, by 38 % on an annual basis. Moreover, ELI Lilly has a number of exciting business Oncology medications, including STX-478 of Scorpion Therapics, which recently paid $ 2.5 billion.
All this means that despite the tremendous success of the GLP-1S, ELI Lilly has many other reasons for inspiration for optimism among investors.
Before you think about Eli Lilly and Company, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … and Eli Lilly and Company were not in the list.
While Eli Lilly and Company currently has a “moderate purchase” classification among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Marketbeat has released a list of 10 cheap shares that have been ignored by the market and may be dangerously denied its value. Enter your email address and add to know the companies that set the list.
